Is evista (raloxifene) as effective as tamoxifen in reducing breast cancer?

Yes (and no): The study of tamoxifen and Raloxifene (star) trial compared the effectiveness of these two drugs in the prevention of breast cancer and found them to be equally effective, with a 50% reduction in invasive breast cancer as compared to placebo. However, only tamoxifen reduced the rate of carcinoma in situ (dcis, lcis).

For invasive cancer: Evista (raloxifene) and tamoxifen were compared in the star trial. The results showed that Evista (raloxifene) was just as effective as reducing the risk of invasive cancer as tamoxifen with fewer side effects. There was no difference in the risk of developing dcis, ore ductal carcinoma in-situ.